Motif Bio plc (NASDAQ: MTFB) saw its shares make small progress, as the New York-based company, a clinical-stage biopharmaceutical company specializing in developing novel antibiotics, announced today that new iclaprim data are being presented at a medical research congress in Amsterdam.
The company announced in a news release Tuesday that larger-size acute bacterial skin and skin structure infection (ABSSSI) lesions may be more difficult to treat.
However, the release goes on to say, clearance of bacteremia has been seen in patients treated with iclaprim versus vancomycin in pooled analysis of REVIVE Phase III study results
Secondary bacteremia is a complication among patients with ABSSSI and is associated with increased morbidity and mortality. A post-hoc analysis evaluated bacteremia outcomes in patients in the REVIVE trials.
A pharmacokinetic analysis of iclaprim-treated patients in the REVIVE Phase III trials evaluated iclaprim clearance and concentration. Age had a small effect on clearance and with it on AUC.
Clearance decreased by about 10% for each decade over 50 years. Clearance was not affected by weight, gender, renal function, hepatic function or race.
The Company’s lead product candidate is iclaprim. Motif Bio is seeking approval of iclaprim from the U.S. Food & Drug Administration for the treatment of ABSSSI. More than 3.6 million patients with ABSSSI are hospitalized annually in the U.S. It is estimated that up to 26% of those who are hospitalized, ABSSSI patients have renal impairment.
Shares in MTFB added 0.4% to $2.16
